Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 2/20 | 0.77 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.71 |
| ▸ | PKM | P14618 | 1/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.66 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.56 |
| ▸ | IDO1 | P14902 | 1/20 | 0.56 |
| ▸ | LDHA | P00338 | 1/20 | 0.56 |
| ▸ | METAP2 | P50579 | 1/20 | 0.51 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.51 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.51 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.50 |
| ▸ | MAP3K8 | P41279 | 1/20 | 0.47 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.47 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.46 |
| ▸ | PFKFB4 | Q16877 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30786304 | 0.80 | ALDH1A1 (0.75) | XDHKDM4EPKMALDH1A1MEN1 | |
| SCHEMBL9182513 | 0.79 | ALDH1A1 (0.56) | XDHKDM4EPKMALDH1A1MEN1 | |
| SCHEMBL5606179 | 0.78 | MEN1 (0.59) | XDHKDM4EPKMALDH1A1MEN1 | |
| SCHEMBL2445769 | 0.77 | XDH (0.52) | XDHKDM4EPKMALDH1A1MEN1 | |
| SCHEMBL8171724 | 0.77 | XDH (0.69) | XDHALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL30786295 | 0.77 | XDH (0.59) | XDHKDM4EPKMALDH1A1MEN1 | |
| SCHEMBL8294492 | 0.76 | ALDH1A1 (0.73) | XDHKDM4EPKMALDH1A1MEN1 | |
| SCHEMBL8429622 | 0.76 | GAA (1.00) | XDHKDM4EPKMALDH1A1MEN1 | |
| SCHEMBL5382098 | 0.75 | XDH (0.63) | XDHKDM4EPKMALDH1A1PDE3B | |
| SCHEMBL23066466 | 0.74 | ALDH1A1 (0.61) | KDM4EPKMALDH1A1L3MBTL1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2246348-A1 | Coupling reactions useful in the preparation of (1h-tetrazol-5-yl)-biphenyl derivatives | Novartis AG (CH) | 2010-11-03 | — | — | EP | disclosed |
| US-20100256109-A1 | Azetidines As EP2 Antagonists | SKERRATT SARAH ELIZABETH | 2010-10-07 | — | — | US | disclosed |
| US-20100152458-A1 | COUPLING REACTIONS USEFUL IN THE PREPARATION OF (1H-TETRAZOL-5-YL) BIPHENYL DERIVATIVES | NOVARTIS PHARMACEUTICALS CORPORATION | 2010-06-17 | — | — | US | disclosed |
| US-7700784-B2 | Coupling reactions useful in the preparation of (1h-tetrazol-5-yl) biphenyl derivatives | NOVARTIS AG (CH) | 2010-04-20 | — | — | US | disclosed |
| US-20070129413-A1 | Coupling reactions useful in the preparation of (1h-tetrazol-5-yl) biphenyl derivatives | NOVARTIS PHARMACEUTICALS CORPORATION | 2007-06-07 | — | — | US | disclosed |
| EP-1716140-A1 | COUPLING REACTIONS USEFUL IN THE PREPARATION OF (1H-TETRAZOL-5-YL)-BIPHENYL DERIVATIVES | Novartis AG (CH) | 2006-11-02 | — | — | EP | disclosed |
| WO-2005075462-A1 | COUPLING REACTIONS USEFUL IN THE PREPARATION OF (1H-TETRAZOL-5-YL)-BIPHENYL DERIVATIVES | NOVARTIS AG (CH) | 2005-08-18 | — | — | WO | disclosed |
| EP-0760814-A1 | A PROCESS FOR PREPARING 1-BUTYL-2-[2'-(2H-TETRAZOL-5-YL)-BIPHENYL-4-YLMETHYL]-1H-INDOLE-3-CARBOXYLIC ACID | SYNTEX (U.S.A.) INC. (US) | 1997-03-12 | — | — | EP | disclosed |
| EP-0760815-A1 | PROCESSES FOR PREPARING 1-BUTYL-2-[2'-(2H-TETRAZOL-5-YL)-BIPHENYL-4-YLMETHYL]-1H-INDOLE-3-CARBOXYLIC ACID | SYNTEX (U.S.A.) INC. (US) | 1997-03-12 | — | — | EP | disclosed |
| US-5527918-A | Processes for preparing 1-butyl-2-[2'-(2H-tetrazol-5-yl) biphenyl-4-ylmethyl]-1H-indole-3-carboxylic acid | SYNTEX (U.S.A.) INC. (US) | 1996-06-18 | — | — | US | disclosed |
| WO-1995032961-A1 | A PROCESS FOR PREPARING 1-BUTYL-2-[2'-(2H-TETRAZOL-5-YL)-BIPHENYL-4-YLMETHYL]-1H-INDOLE-3-CARBOXYLIC ACID | SYNTEX (U.S.A.) INC. (US) | 1995-12-07 | — | — | WO | disclosed |
| WO-1995032962-A1 | PROCESSES FOR PREPARING 1-BUTYL-2-[2'-(2H-TETRAZOL-5-YL)-BIPHENYL-4-YLMETHYL]-1H-INDOLE-3-CARBOXYLIC ACID | SYNTEX (U.S.A.) INC. (US) | 1995-12-07 | — | — | WO | disclosed |
| US-5468867-A | Process for preparing1-butyl-2-[2'-(2H-tetrazol-5-yl)biphenyl-4-ylmethyl1-1H-indole-3-carboxylic acid | SYNTEX (U.S.A.) INC. (US) | 1995-11-21 | — | — | US | disclosed |
| US-5446121-A | Processes for preparing 1-butyl-2-[2'-(2H-tetrazol-5-yl) biphenyl-4-ylmethyl]-1H-indole-3-carboxylic acid | SYNTEX (U.S.A.) INC. (US) | 1995-08-29 | — | — | US | disclosed |
| US-5412102-A | Processes for preparing 1-butyl-2-[2'-(2H-tetrazol-5-yl) biphenyl-4-ylmethyl]-1H-indole-3-carboxylic acid | SYNTEX (U.S.A.) INC. (US) | 1995-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152458-A1 | COUPLING REACTIONS USEFUL IN THE PREPARATION OF (1H-TETRAZOL-5-YL) BIPHENYL DERIVATIVES | AGTR1, AGTR2, AGT | XDH 2655/4885KDM4E 2767/4885PKM 2370/4885 |
| US-20100256109-A1 | Azetidines As EP2 Antagonists | PTGER2, PTGER1, PTGDR2 | XDH 2554/4885KDM4E 617/4885PKM 1652/4885 |
| US-20070129413-A1 | Coupling reactions useful in the preparation of (1h-tetrazol-5-yl) biphenyl derivatives | AGTR1, AGTR2, AGT | XDH 2930/4885KDM4E 4414/4885PKM 2730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.